fluoride/breast neoplasms

Purpose: To establish whether non-invasive measurement of changes in 18F-fluoride metabolic flux to bone mineral (Ki) by positron emission tomography/ computed tomography (PET/CT) can provide incremental value in response assessment of bone metastases in breast cancer compared to maximum and mean

OBJECTIVE So far, no studies comparing (18)F-Fluoride-PET/CT and MDCT for the detection of bone metastases are available. We compared the accuracy of (18)F-Fluoride-PET/CT (MDCT: 3.75 mm thickness-image-reconstruction), whole-body Multi-Detector-CT (MDCT: 1.25 mm thickness-image-reconstruction) and

We report the case of a breast cancer patient in whom a two-phase ¹⁸F-sodium-fluoride (¹⁸F-NaF) bone PET/CT was useful for detecting hidden bone metastases and assessing treatment response. The patient underwent a two-phase bone PET/CT to evaluate a newly developed lesion found

Intense FDG uptake by bone marrow following recent chemotherapy limits evaluation for osseous metastases. The impact of marrow rebound on accuracy of (18)F-fluoride PET/CT is unclear. A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout

The most common site of metastasis for breast cancer is bone. Quantitative (18)F-fluoride PET can estimate the kinetics of fluoride incorporation into bone as a measure of fluoride transport, bone formation, and turnover. The purpose of this analysis was to evaluate the accuracy and precision of

OBJECTIVE In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define

In 23 cases of breast cancer treated conservatively using external beam and interstitial radiotherapy, lithium fluoride thermoluminescent dosimetry has been used to measure the radiation dose received by the breast tissue at depth. Thirty-six investigations were made using a number of lithium

OBJECTIVE Bone-specific radiotracers are known to accumulate in breast lesions. Tc-99m diphosphonates have been widely studied in differentiating breast lesions. In this retrospective study, we aimed to assess the uptake of the bone-specific PET radiotracer, F-18 fluoride (NaF), in primary breast

BACKGROUND Clinically-relevant animal models and appropriate imaging diagnostic tools are essential to study cancer and develop novel therapeutics. We evaluated a model of bone metastasis in nude rats by micro-PET and bioluminescence imaging. METHODS A bone metastasis model was produced by

OBJECTIVE To characterise the uptake of 18F in skeletal metastases from breast cancer using positron emission tomography (PET) and to relate these findings to the appearance on CT. METHODS PET with 18F and CT were performed in five patients with multiple skeletal metastases from breast cancer. The

OBJECTIVE To establish whether first-order statistical features from [18F]fluoride and 2-deoxy-2-[18F] fluoro-D-glucose ([18F]FDG) positron emission tomography/x-ray computed tomography (PET/CT) demonstrate incremental value in skeletal metastasis response assessment compared with maximum

OBJECTIVE The superiority of sodium F-fluoride PET (F-PET)/computed tomography (CT) over planar and single field-of-view single-photon emission computed tomography (SPECT) bone scintigraphy with Tc-methylene diphosphonate in bone metastases detection has been established. The present study

BACKGROUND Although single-photon emission computed tomography (SPECT)/computed tomography (CT) plays a major role in the characterization of equivocal lesions on bone scintigraphy, it remains equivocal in a fraction of these patients. We evaluated the additional value of cocktail F-18 sodium

OBJECTIVE To compare 2-deoxy-2-((18)F)fluoro-D-glucose((18)F-FDG) and (18)F-sodium ((18)F-NaF) positron emission tomography/computed tomography (PET/CT) accuracy in breast cancer patients with clinically/radiologically suspected or known bone metastases. METHODS A total of 45 consecutive patients

To compare [¹⁸F]-fluorodeoxyglucose (FDG) and [¹⁸F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction